The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars

The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced breast and gastric cancer in which HER2 is overexpressed. Several biosimilar versions of trastuzumab are expected to enter t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier, Liese, Declerck, Paul, Simoens, Steven, Neven, Patrick, Vulto, Arnold G., Huys, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738325/
https://www.ncbi.nlm.nih.gov/pubmed/31257362
http://dx.doi.org/10.1038/s41416-019-0480-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738325/
https://www.ncbi.nlm.nih.gov/pubmed/31257362
http://dx.doi.org/10.1038/s41416-019-0480-z

Ejemplares similares